2
Clinical Trials associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in participants of Kite-sponsored interventional studies.
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
The goal of this clinical study is to learn more about the safety and dosing of the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory B-cell lymphoma.
100 Clinical Results associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
100 Translational Medicine associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
100 Patents (Medical) associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)
100 Deals associated with Autologous Anti-CD19/CD20 CAR T-cell Therapy(Kite Pharma, Inc)